{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:22:28Z","timestamp":1791818548365,"version":"4.3.4"},"reference-count":85,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["263755"],"award-info":[{"award-number":["263755"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["135937"],"award-info":[{"award-number":["135937"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Tumor-associated trypsin inhibitor (TATI) was originally isolated from the urine of a patient with ovarian cancer. It was later shown to be produced by many other tumors and several normal tissues. It had earlier been isolated from the pancreas and was hence called pancreatic secretory trypsin inhibitor (PSTI). It belongs to a family of protease inhibitors presently called serine peptidase inhibitor Kazal type (SPINK). In the SPINK family TATI\/PSTI is SPINK1, which is the name used in this review.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONTENT<\/jats:title><jats:p>In addition to being a protease inhibitor, SPINK1 also acts as an acute-phase reactant and a growth factor. Furthermore, it has been shown to modulate apoptosis. Overexpression of SPINK1 predicts an unfavorable outcome in several cancers and determination of SPINK1 in serum can be used to identify patients at increased risk of aggressive disease. Thus serum SPINK1 can be used as a prognostic tumor marker. Because SPINK1 acts as a growth factor and an inhibitor of apoptosis in some cancers, it has also been suggested that it can be a therapeutic target in cancer. However, because SPINK1 is the major physiological inhibitor of trypsin, inhibition of SPINK1 may increase the risk of pancreatitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>SUMMARY<\/jats:title><jats:p>Taking into account the many functions of SPINK1, assessing the role of SPINK1 in cancer has several potentially important clinical applications ranging from a biomarker to a potential new target for cancer therapy.<\/jats:p><\/jats:sec>","DOI":"10.1373\/clinchem.2015.241513","type":"journal-article","created":{"date-parts":[[2015,12,12]],"date-time":"2015-12-12T01:24:22Z","timestamp":1449883462000},"page":"449-457","source":"Crossref","is-referenced-by-count":76,"title":["Emerging Roles of SPINK1 in Cancer"],"prefix":"10.1093","volume":"62","author":[{"given":"Kati","family":"R\u00e4s\u00e4nen","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, University of Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Itkonen","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, University of Helsinki, Finland"},{"name":"Laboratory Division (HUSLAB), Helsinki University Central Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"Koistinen","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, University of Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf-H\u00e5kan","family":"Stenman","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, University of Helsinki, Finland"},{"name":"Laboratory Division (HUSLAB), Helsinki University Central Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,3,1]]},"reference":[{"key":"2020022605322909700_B1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cca.2014.02.014","article-title":"TATI as a biomarker","volume":"431","author":"Itkonen","year":"2014","journal-title":"Clin Chim Acta"},{"key":"2020022605322909700_B2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2174\/0929866054395356","article-title":"Human mesotrypsin defies natural trypsin inhibitors: from passive resistance to active destruction","volume":"12","author":"Sahin-Toth","year":"2005","journal-title":"Protein Pept Lett"},{"key":"2020022605322909700_B3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1515\/bchm2.1984.365.2.819","article-title":"Demonstration of a new acrosin inhibitor in human seminal plasma","volume":"365","author":"Huhtala","year":"1984","journal-title":"Hoppe Seylers Z Physiol Chem"},{"key":"2020022605322909700_B4","first-page":"671","article-title":"A radioimmunoassay for measurement of human pancreatic secretory trypsin inhibitor in different body fluids","volume":"359","author":"Eddeland","year":"1978","journal-title":"Hoppe Seylers Z Physiol Chem"},{"key":"2020022605322909700_B5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0378-1119(93)90306-N","article-title":"Identification of the IL-6-responsive element in an acute-phase-responsive human pancreatic secretory trypsin inhibitor-encoding gene","volume":"131","author":"Yasuda","year":"1993","journal-title":"Gene"},{"key":"2020022605322909700_B6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0003-9861(83)90309-0","article-title":"Primary amino acid sequence similarity between human epidermal growth factor-urogastrone, human pancreatic secretory trypsin inhibitor, and members of porcine secretin family","volume":"226","author":"Scheving","year":"1983","journal-title":"Arch Biochem Biophys"},{"key":"2020022605322909700_B7","first-page":"155","article-title":"Stimulation of DNA synthesis in human fibroblasts by human pancreatic secretory trypsin inhibitor","volume":"50","author":"Ogawa","year":"1985","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"2020022605322909700_B8","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1016\/S0021-9258(19)57226-X","article-title":"Two apparent human endothelial cell growth factors from human hepatoma cells are tumor-associated proteinase inhibitors","volume":"261","author":"McKeehan","year":"1986","journal-title":"J Biol Chem"},{"key":"2020022605322909700_B9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0006-291X(87)91013-8","article-title":"Competition of a growth stimulating-\/cholecystokinin (CCK) releasing-peptide (monitor peptide) with epidermal growth factor for binding to 3T3 fibroblasts","volume":"145","author":"Fukuoka","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"2020022605322909700_B10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-4827(02)00098-8","article-title":"Epidermal growth factor receptor: mechanisms of activation and signalling","volume":"284","author":"Jorissen","year":"2003","journal-title":"Exp Cell Res"},{"key":"2020022605322909700_B11","first-page":"2375","article-title":"Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2","volume":"50","author":"Koivunen","year":"1990","journal-title":"Cancer Res"},{"key":"2020022605322909700_B12","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/clinchem\/48.8.1206","article-title":"Tumor-associated trypsin inhibitor","volume":"48","author":"Stenman","year":"2002","journal-title":"Clin Chem"},{"key":"2020022605322909700_B13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ijc.2910300110","article-title":"Immunochemical demonstration of an ovarian cancer-associated urinary peptide","volume":"30","author":"Stenman","year":"1982","journal-title":"Int J Cancer"},{"key":"2020022605322909700_B14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/ijc.2910310606","article-title":"Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy","volume":"31","author":"Huhtala","year":"1983","journal-title":"Int J Cancer"},{"key":"2020022605322909700_B15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1471-0528.1998.tb10150.x","article-title":"Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in Stage III epithelial ovarian cancer","volume":"105","author":"Venesmaa","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"2020022605322909700_B16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/00365519109104622","article-title":"Evaluation of TATI and other markers in solid tumors","volume":"207","author":"Taccone","year":"1991","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"2020022605322909700_B17","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/bjc.1988.67","article-title":"Tumour-associated trypsin inhibitor (TATI) in ovarian cancer","volume":"57","author":"Halila","year":"1988","journal-title":"Br J Cancer"},{"key":"2020022605322909700_B18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjc.1987.175","article-title":"Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA","volume":"56","author":"Halila","year":"1987","journal-title":"Br J Cancer"},{"key":"2020022605322909700_B19","first-page":"973","article-title":"Claudin-5 is associated with elevated TATI and CA125 levels in mucinous ovarian borderline tumors","volume":"35","author":"Nissi","year":"2015","journal-title":"Anticancer Res"},{"key":"2020022605322909700_B20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/10408360500523852","article-title":"Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor","volume":"43","author":"Paju","year":"2006","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2020022605322909700_B21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/00365510151097584","article-title":"Trypsinogen-1, -2 and tumour-associated trypsin inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas","volume":"61","author":"Hedstrom","year":"2001","journal-title":"Scand J Clin Lab Invest"},{"key":"2020022605322909700_B22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/bjc.1986.176","article-title":"Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases","volume":"54","author":"Haglund","year":"1986","journal-title":"Br J Cancer"},{"key":"2020022605322909700_B23","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.pan.2013.06.008","article-title":"Cyst fluid SPINK1 may help to differentiate benign and potentially malignant cystic pancreatic lesions","volume":"13","author":"Raty","year":"2013","journal-title":"Pancreatology"},{"key":"2020022605322909700_B24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000243732","article-title":"Pre-diagnostic levels of anionic trypsinogen, cationic trypsinogen, and pancreatic secretory trypsin inhibitor in relation to pancreatic cancer risk","volume":"10","author":"Johansen","year":"2010","journal-title":"Pancreatology"},{"key":"2020022605322909700_B25","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/MPA.0000000000000166","article-title":"CFTR, SPINK1, PRSS1, and CTRC mutations are not associated with pancreatic cancer in German patients","volume":"43","author":"Schubert","year":"2014","journal-title":"Pancreas"},{"key":"2020022605322909700_B26","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/0016-5085(90)91170-B","article-title":"Pancreatic secretory trypsin inhibitor stimulates the growth of rat pancreatic carcinoma cells","volume":"99","author":"Freeman","year":"1990","journal-title":"Gastroenterology"},{"key":"2020022605322909700_B27","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1541-7786.MCR-08-0567","article-title":"Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor","volume":"7","author":"Ozaki","year":"2009","journal-title":"Mol Cancer Res"},{"key":"2020022605322909700_B28","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.eururo.2007.01.096","article-title":"Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells","volume":"52","author":"Paju","year":"2007","journal-title":"Eur Urol"},{"key":"2020022605322909700_B29","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1158\/1078-0432.CCR-09-2505","article-title":"Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer","volume":"16","author":"Leinonen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2020022605322909700_B30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/pros.22989","article-title":"Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India","volume":"75","author":"Ateeq","year":"2015","journal-title":"Prostate"},{"key":"2020022605322909700_B31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccr.2008.04.016","article-title":"The role of SPINK1 in ETS rearrangement-negative prostate cancers","volume":"13","author":"Tomlins","year":"2008","journal-title":"Cancer Cell"},{"key":"2020022605322909700_B32","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/1055-9965.EPI-13-0333-T","article-title":"Loss of PTEN is associated with aggressive behavior in ERG positive prostate cancer","volume":"22","author":"Leinonen","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2020022605322909700_B33","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1158\/1078-0432.CCR-13-1341","article-title":"SPINK1 protein expression and prostate cancer progression","volume":"20","author":"Flavin","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2020022605322909700_B34","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/cncr.29233","article-title":"Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer","volume":"121","author":"Terry","year":"2015","journal-title":"Cancer"},{"key":"2020022605322909700_B35","doi-asserted-by":"crossref","first-page":"72ra17","DOI":"10.1126\/scitranslmed.3001498","article-title":"Therapeutic targeting of SPINK1-positive prostate cancer","volume":"3","author":"Ateeq","year":"2011","journal-title":"Sci Transl Med"},{"key":"2020022605322909700_B36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/pros.22787","article-title":"Serine protease inhibitor kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer","volume":"74","author":"Wang","year":"2014","journal-title":"Prostate"},{"key":"2020022605322909700_B37","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/ijc.2910550505","article-title":"Specific expression of the pancreatic-secretory-trypsin-inhibitor (PSTI) gene in hepatocellular carcinoma","volume":"55","author":"Ohmachi","year":"1993","journal-title":"Int J Cancer"},{"key":"2020022605322909700_B38","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ejca.2006.11.020","article-title":"Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma","volume":"43","author":"Lee","year":"2007","journal-title":"Eur J Cancer"},{"key":"2020022605322909700_B39","doi-asserted-by":"crossref","first-page":"e59459","DOI":"10.1371\/journal.pone.0059459","article-title":"Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker","volume":"8","author":"Marshall","year":"2013","journal-title":"PLoS One"},{"key":"2020022605322909700_B40","first-page":"2021","article-title":"Gene expression analysis for evaluation of potential biomarkers in hepatocellular carcinoma","volume":"35","author":"Hass","year":"2015","journal-title":"Anticancer Res"},{"key":"2020022605322909700_B41","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3109\/00365521.2013.805810","article-title":"Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-\u03b2 (hCG\u03b2) in patients with hepatocellular carcinoma","volume":"48","author":"Lyytinen","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"2020022605322909700_B42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10495-008-0193-x","article-title":"Tumor-associated protein SPIK\/TATI suppresses serine protease dependent cell apoptosis","volume":"13","author":"Lu","year":"2008","journal-title":"Apoptosis"},{"key":"2020022605322909700_B43","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2567.2011.03498.x","article-title":"Role of the inflammatory protein serine protease inhibitor Kazal in preventing cytolytic granule granzyme A-mediated apoptosis","volume":"134","author":"Lu","year":"2011","journal-title":"Immunology"},{"issue":"Pt 1","key":"2020022605322909700_B44","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1042\/bj20021891","article-title":"Purification and identification of a binding protein for pancreatic secretory trypsin inhibitor: a novel role of the inhibitor as an anti-granzyme A","volume":"372","author":"Tsuzuki","year":"2003","journal-title":"Biochem J"},{"key":"2020022605322909700_B45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0092-8674(92)90359-K","article-title":"Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A","volume":"71","author":"Shiver","year":"1992","journal-title":"Cell"},{"key":"2020022605322909700_B46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00006676-199604000-00015","article-title":"Extrapancreatic origin of the pancreatic secretory trypsin inhibitor as an acute-phase reactant","volume":"12","author":"Jonsson","year":"1996","journal-title":"Pancreas"},{"key":"2020022605322909700_B47","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/01635581.2013.770043","article-title":"Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC\/PRF\/5 hepatoma cells","volume":"65","author":"Ghasemi","year":"2013","journal-title":"Nutr Cancer"},{"key":"2020022605322909700_B48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365510152567068","article-title":"Serum tumour markers CA 15\u20133, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer","volume":"61","author":"Sjostrom","year":"2001","journal-title":"Scand J Clin Lab Invest"},{"key":"2020022605322909700_B49","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s13277-013-1366-y","article-title":"A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer","volume":"35","author":"El-mezayen","year":"2014","journal-title":"Tumour Biol"},{"key":"2020022605322909700_B50","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/emmm.201100150","article-title":"Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer","volume":"3","author":"Soon","year":"2011","journal-title":"EMBO Mol Med"},{"key":"2020022605322909700_B51","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1038\/onc.2008.42","article-title":"Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells","volume":"27","author":"Gouyer","year":"2008","journal-title":"Oncogene"},{"key":"2020022605322909700_B52","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/sj.bjc.6605047","article-title":"High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer","volume":"100","author":"Gaber","year":"2009","journal-title":"Br J Cancer"},{"key":"2020022605322909700_B53","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1186\/1471-2407-10-498","article-title":"Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients","volume":"10","author":"Gaber","year":"2010","journal-title":"BMC Cancer"},{"key":"2020022605322909700_B54","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s12253-015-9949-0","article-title":"Serine protease inhibitor kazal type 1 (SPINK1) promotes proliferation of colorectal cancer through the epidermal growth factor as a prognostic marker","volume":"21","author":"Chen","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"2020022605322909700_B55","doi-asserted-by":"crossref","first-page":"e76906","DOI":"10.1371\/journal.pone.0076906","article-title":"Concomitant tumor expression of EGFR and TATI\/SPINK1 associates with better prognosis in colorectal cancer","volume":"8","author":"Koskensalo","year":"2013","journal-title":"PLoS One"},{"key":"2020022605322909700_B56","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/1541-7786.MCR-14-0581","article-title":"SPINK1 status in colorectal cancer, impact on proliferation, and role in colitis-associated cancer","volume":"13","author":"Ida","year":"2015","journal-title":"Mol Cancer Res"},{"key":"2020022605322909700_B57","first-page":"715","article-title":"Distribution and expression of pancreatic secretory trypsin inhibitor and its possible role in epithelial restitution","volume":"148","author":"Marchbank","year":"1996","journal-title":"Am J Pathol"},{"key":"2020022605322909700_B58","doi-asserted-by":"crossref","first-page":"G697","DOI":"10.1152\/ajpgi.90565.2008","article-title":"Pancreatic secretory trypsin inhibitor is a major motogenic and protective factor in human breast milk","volume":"296","author":"Marchbank","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2020022605322909700_B59","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1038\/oncsis.2015.23","article-title":"SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression","volume":"4","author":"Tiwari","year":"2015","journal-title":"Oncogenesis"},{"key":"2020022605322909700_B60","first-page":"95","article-title":"Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer","volume":"28","author":"Hotakainen","year":"2006","journal-title":"Int J Oncol"},{"key":"2020022605322909700_B61","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00345-011-0727-7","article-title":"Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder","volume":"30","author":"Patschan","year":"2012","journal-title":"World J Urol"},{"key":"2020022605322909700_B62","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.urolonc.2012.06.011","article-title":"Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy","volume":"31","author":"Rink","year":"2013","journal-title":"Urol Oncol"},{"key":"2020022605322909700_B63","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0090-4295(03)00329-7","article-title":"Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer","volume":"62","author":"Kelloniemi","year":"2003","journal-title":"Urology"},{"key":"2020022605322909700_B64","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.urology.2008.04.009","article-title":"Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21\u20131, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma","volume":"72","author":"Gkialas","year":"2008","journal-title":"Urology"},{"key":"2020022605322909700_B65","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00000421-199606000-00013","article-title":"TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19\u20139 for monitoring transitional cell carcinoma of the bladder","volume":"19","author":"Pectasides","year":"1996","journal-title":"Am J Clin Oncol"},{"key":"2020022605322909700_B66","doi-asserted-by":"crossref","first-page":"F382","DOI":"10.1152\/ajprenal.00357.2012","article-title":"Pancreatic secretory trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2","volume":"305","author":"Marchbank","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"2020022605322909700_B67","first-page":"2923","article-title":"The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer","volume":"17","author":"Kemik","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2020022605322909700_B68","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2559.2005.02073.x","article-title":"High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer","volume":"46","author":"Wiksten","year":"2005","journal-title":"Histopathology"},{"key":"2020022605322909700_B69","first-page":"2279","article-title":"Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer","volume":"28","author":"Wiksten","year":"2008","journal-title":"Anticancer Res"},{"key":"2020022605322909700_B70","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3892\/etm.2011.353","article-title":"Development of a survival prediction model for gastric cancer using serine proteases and their inhibitors","volume":"3","author":"Lei","year":"2012","journal-title":"Exp Ther Med"},{"key":"2020022605322909700_B71","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-5347(05)66584-6","article-title":"Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma","volume":"165","author":"Paju","year":"2001","journal-title":"J Urol"},{"key":"2020022605322909700_B72","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<486::AID-IJC9>3.0.CO;2-O","article-title":"Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients","volume":"83","author":"Lukkonen","year":"1999","journal-title":"Int J Cancer"},{"key":"2020022605322909700_B73","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF02779516","article-title":"Immunoreactive pancreatic secretory trypsin inhibitor in normal, inflammatory and neoplastic gallbladders","volume":"26","author":"Bohe","year":"1991","journal-title":"Gastroenterol Jpn"},{"key":"2020022605322909700_B74","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/j.1572-0241.2006.00612.x","article-title":"Relationship between pancreatic secretory trypsin inhibitor and early recurrence of intrahepatic cholangiocarcinoma following surgical resection","volume":"101","author":"Tonouchi","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"2020022605322909700_B75","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/00365519109104624","article-title":"Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma","volume":"207","author":"Gion","year":"1991","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"2020022605322909700_B76","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000276919","article-title":"Evaluation of TATI and CYFRA 21\u20131 in patients with head and neck squamous cell carcinoma","volume":"59","author":"Goumas","year":"1997","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"2020022605322909700_B77","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/172460089300800203","article-title":"Squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), and tumour-associated trypsin inhibitor (TATI) for monitoring head and neck cancer","volume":"8","author":"Pectasides","year":"1993","journal-title":"Int J Biol Markers"},{"key":"2020022605322909700_B78","first-page":"1247","article-title":"Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow up of stage III cervical cancer","volume":"12","author":"Gitsch","year":"1992","journal-title":"Anticancer Res"},{"key":"2020022605322909700_B79","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/1097-0142(19930315)71:6<1982::AID-CNCR2820710610>3.0.CO;2-G","article-title":"Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening","volume":"71","author":"Jarvisalo","year":"1993","journal-title":"Cancer"},{"key":"2020022605322909700_B80","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.cca.2012.04.001","article-title":"Validation and comparison of tumor-associated trypsin inhibitor (TATI) immunoassays","volume":"413","author":"Janeiro","year":"2012","journal-title":"Clin Chim Acta"},{"key":"2020022605322909700_B81","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0022-1759(93)90201-H","article-title":"Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system","volume":"161","author":"Osman","year":"1993","journal-title":"J Immunol Methods"},{"key":"2020022605322909700_B82","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/bjc.1995.202","article-title":"TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer","volume":"71","author":"Medl","year":"1995","journal-title":"Br J Cancer"},{"key":"2020022605322909700_B83","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1373\/clinchem.2005.056861","article-title":"Application of proteomic technology in identifying pancreatic secretory trypsin inhibitor variants in urine of patients with pancreatitis","volume":"52","author":"Valmu","year":"2006","journal-title":"Clin Chem"},{"key":"2020022605322909700_B84","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"2020022605322909700_B85","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1186\/gb-2008-9-9-r139","article-title":"Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues","volume":"9","author":"Kilpinen","year":"2008","journal-title":"Genome Biol"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/62\/3\/449\/32643799\/clinchem0449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/62\/3\/449\/32643799\/clinchem0449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T02:04:17Z","timestamp":1653789857000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/62\/3\/449\/5611713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":85,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,1]]},"published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2015.241513","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,3,1]]},"published":{"date-parts":[[2016,3,1]]}}}